The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Insmed Inc (NASDAQ: INSM) closed the day trading at $97.62 down -3.00% from the previous closing price of $100.64. In other words, the price has decreased by -$3.00 from its previous closing price. On the day, 3.83 million shares were traded. INSM stock price reached its highest trading level at $100.475 during the session, while it also had its lowest trading level at $97.34.
Ratios:
For a better understanding of INSM, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.44 and its Current Ratio is at 5.86. In the meantime, Its Debt-to-Equity ratio is 13.21 whereas as Long-Term Debt/Eq ratio is at 13.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on May 13, 2025, initiated with a Buy rating and assigned the stock a target price of $105.
On February 25, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $100.
On April 23, 2024, Truist started tracking the stock assigning a Buy rating and target price of $48.Truist initiated its Buy rating on April 23, 2024, with a $48 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 01 ’25 when Lewis William bought 6,830 shares for $98.30 per share.
Bonstein Sara sold 57,765 shares of INSM for $5,879,089 on Jun 23 ’25. The Chief Financial Officer now owns 93,536 shares after completing the transaction at $101.78 per share. On Jun 23 ’25, another insider, Bonstein Sara, who serves as the Officer of the company, bought 57,765 shares for $101.75 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INSM now has a Market Capitalization of 18543017984 and an Enterprise Value of 18436890624. For the stock, the TTM Price-to-Sale (P/S) ratio is 48.67 while its Price-to-Book (P/B) ratio in mrq is 179.08. Its current Enterprise Value per Revenue stands at 48.387 whereas that against EBITDA is -21.695.
Stock Price History:
The Beta on a monthly basis for INSM is 0.90, which has changed by 0.5745162 over the last 52 weeks, in comparison to a change of 0.11937654 over the same period for the S&P500. Over the past 52 weeks, INSM has reached a high of $106.83, while it has fallen to a 52-week low of $60.40. The 50-Day Moving Average of the stock is 24.16%, while the 200-Day Moving Average is calculated to be 30.25%.
Shares Statistics:
Over the past 3-months, INSM traded about 3.74M shares per day on average, while over the past 10 days, INSM traded about 6762340 shares per day. A total of 189.95M shares are outstanding, with a floating share count of 185.72M. Insiders hold about 2.23% of the company’s shares, while institutions hold 104.81% stake in the company. Shares short for INSM as of 1749772800 were 11650625 with a Short Ratio of 3.12, compared to 1747267200 on 16467942. Therefore, it implies a Short% of Shares Outstanding of 11650625 and a Short% of Float of 6.88.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Insmed Inc (INSM) is currently in the spotlight, with 13.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$1.37, with high estimates of -$1.24 and low estimates of -$1.53.
Analysts are recommending an EPS of between -$3.79 and -$5.82 for the fiscal current year, implying an average EPS of -$5.19. EPS for the following year is -$3.58, with 13.0 analysts recommending between -$2.33 and -$5.11.
Revenue Estimates
15 analysts predict $103.4M in revenue for the current quarter. It ranges from a high estimate of $107M to a low estimate of $98.7M. As of the current estimate, Insmed Inc’s year-ago sales were $90.34MFor the next quarter, 15 analysts are estimating revenue of $113.67M. There is a high estimate of $118.44M for the next quarter, whereas the lowest estimate is $108.5M.
A total of 18 analysts have provided revenue estimates for INSM’s current fiscal year. The highest revenue estimate was $491M, while the lowest revenue estimate was $441.1M, resulting in an average revenue estimate of $464.28M. In the same quarter a year ago, actual revenue was $363.71MBased on 17 analysts’ estimates, the company’s revenue will be $993.67M in the next fiscal year. The high estimate is $1.41B and the low estimate is $845.97M.
